426c.Mod.Core-C4b

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network

Conditions

Chronic HIV InfectionHIVHIV Infections

Phase 1

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Active, not recruitingNCT06006546

National Institute of Allergy and Infectious Diseases (NIAID)Chronic HIV Infection

Start: 2024-01-03End: 2026-10-27Updated: 2026-01-14

Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected

Not yet recruitingNCT06613789

HIV Vaccine Trials NetworkHIV Infections

Start: 2026-07-13End: 2027-06-03Target: 22Updated: 2025-12-09

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

RecruitingNCT06796686

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2025-03-17End: 2027-01-15Target: 42Updated: 2025-09-25

Related Papers

GMP Manufacturing and Characterization of the HIV Booster Immunogen HxB2.WT.Core-C4b for Germline Targeting Vaccine Strategies

Vaccines2025-09-18